The estimated Net Worth of Brian Bernick is at least $12.6 millió dollars as of 6 December 2022. Brian Bernick owns over 3,167 units of TherapeuticsMD Inc stock worth over $9,115 and over the last 13 years he sold TXMD stock worth over $11,310,616. In addition, he makes $1,297,940 as Co-Founder at TherapeuticsMD Inc.
Sign up
Brian Bernick TXMD stock SEC Form 4 insiders trading
Brian has made over 31 trades of the TherapeuticsMD Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 3,167 units of TXMD stock worth $5,631 on 6 December 2022.
The largest trade he's ever made was selling 1,600,000 units of TherapeuticsMD Inc stock on 26 August 2013 worth over $2,480,000. On average, Brian trades about 150,178 units every 71 days since 2012. As of 6 December 2022 he still owns at least 5,127 units of TherapeuticsMD Inc stock.
You can see the complete history of Brian Bernick stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Bernick biography
Dr. Brian A. Bernick M.D. serves as Co-Founder of the Company. He has served as co-founder and director of our company since October 2011 and co-founder and director of vitaMedMD, from April 2008 to October 2011. Dr. Bernick previously served as our Chief Clinical Officer from November 2013 to May 2018 and as our Chief Medical Officer from February 2012 until November 2013. Dr. Bernick is a board-certified obstetrician/gynecologist with over 25 years of clinical medical experience. Dr. Bernick was the Department Chair of Obstetrics and Gynecology at Boca Raton Regional Hospital and served on that hospital’s Medical Executive Board as well as the Board of Directors of the Palm Beach Medical Society and VitalMD Group Holding, LLC, one of the largest physician-owned and -managed medical groups in Florida. Dr. Bernick has served on the American College of Obstetricians and Gynecologists’ (ACOG) national committee on Professional Liability. Dr. Bernick is the recipient of several national and regional awards, including recognition by his peers as one of the top doctor’s in his specialty by Castle Connolly as well as the recipient of the American Medical Association Foundation’s Leadership Award. Dr. Bernick has over 100 peer-reviewed publications and presentations of original research at medical conferences. Dr. Bernick is responsible for numerous U.S. and foreign patents focusing on drug therapies and analysis. Dr. Bernick is an affiliate associate professor of obstetrics and gynecology at Florida Atlantic University College of Medicine. Dr. Bernick holds a B.A. in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residency at the University of Pennsylvania.
What is the salary of Brian Bernick?
As the Co-Founder of TherapeuticsMD Inc, the total compensation of Brian Bernick at TherapeuticsMD Inc is $1,297,940. There are 1 executives at TherapeuticsMD Inc getting paid more, with John Milligan having the highest compensation of $1,440,640.
How old is Brian Bernick?
Brian Bernick is 51, he's been the Co-Founder of TherapeuticsMD Inc since 2020. There are 15 older and 11 younger executives at TherapeuticsMD Inc. The oldest executive at TherapeuticsMD Inc is Tommy Thompson, 78, who is the Independent Chairman of the Board.
What's Brian Bernick's mailing address?
Brian's mailing address filed with the SEC is 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431.
Insiders trading at TherapeuticsMD Inc
Over the last 13 years, insiders at TherapeuticsMD Inc have traded over $21,656,853 worth of TherapeuticsMD Inc stock and bought 721,732 units worth $2,299,099 . The most active insiders traders include Cooper C. Collins, Brian Bernick és Robert G Finizio. On average, TherapeuticsMD Inc executives and independent directors trade stock every 29 days with the average trade being worth of $272,607. The most recent stock trade was executed by John C.K. Iv Milligan on 25 October 2019, trading 72,000 units of TXMD stock currently worth $198,000.
What does TherapeuticsMD Inc do?
therapeuticsmd, inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. we create products to address the unique changes and challenges women experience through every stage of their lives. with momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. this includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitamedmd® and bocagreenmd® brands. see our community guidelines: https://www.therapeuticsmd.com/social-media-community-guidelines
What does TherapeuticsMD Inc's logo look like?
Complete history of Brian Bernick stock trades at TherapeuticsMD és TherapeuticsMD Inc
TherapeuticsMD Inc executives and stock owners
TherapeuticsMD Inc executives and other stock owners filed with the SEC include:
-
John Milligan,
President, Secretary -
Brian Bernick,
Co-Founder -
Robert Finizio,
Chief Executive Officer and Director -
Robert G. Finizio,
Co-Founder & Vice Chair -
Mitchell Krassan,
Chief Strategy and Performance Officer -
John C. K. Milligan IV,
Chief Exec. Officer of VitaCare Prescription Services -
Michael Donegan,
Vice President - Finance -
Tommy Thompson,
Independent Chairman of the Board -
Cooper Collins,
Independent Director -
J. Martin Carroll,
Independent Director -
Angus Russell,
Independent Director -
Jules Musing,
Independent Director -
Dr. Brian A. Bernick,
Co-Founder & Chief Scientific Officer -
Nichol Ochsner,
Vice President, Investor Relations -
Gail Naughton,
Independent Director -
Karen Ling,
Independent Director -
Paul Bisaro,
Independent Director -
Bharat Warrier,
Chief Manufacturing Officer -
Sebastian Mirkin,
Chief Medical Officer -
Dawn Halkuff,
Chief Commercial Officer -
Marlan Walker,
General Counsel -
John Knighton,
Chief Compliance Officer -
Adam Miller,
Chief Information Officer -
James D'Arecca,
Chief Financial Officer -
Julia M. Amadio,
Chief Product Officer -
Mitchell L. Krassan,
Exec. VP and Chief Strategy & Performance Officer -
Chris Gish,
Sr. VP of Sales -
Michael Donegan,
Chief Accounting Officer & VP of Fin. -
James C. D'Arecca,
Chief Financial Officer -
Hugh O'Dowd M.B.A.,
Pres, CEO & Director -
Robert V Jr La Penta,
Director -
Nicholas Segal,
Director -
Jane F Barlow,
Director -
Daniel A Cartwright,
Chief Financial Officer -
Randall S Stanicky,
Director -
Samuel A Greco,
Director